Peijia Medical Inkomsten in het verleden

Verleden criteriumcontroles 0/6

Peijia Medical is de winst gegroeid met een gemiddeld jaarlijks percentage van 38.7%, terwijl de Medical Equipment industrie de winst jaarlijks groeide met 14.7%. De inkomsten zijn gegroeid met een gemiddelde van 53% per jaar.

Belangrijke informatie

38.7%

Groei van de winst

62.2%

Groei van de winst per aandeel

Medical Equipment Groei van de industrie	13.7%
Inkomstengroei	53.0%
Rendement op eigen vermogen	-11.5%
Nettomarge	-48.6%
Laatste winstupdate	30 Jun 2024

Recente prestatie-updates uit het verleden

Recent updates

Why Investors Shouldn't Be Surprised By Peijia Medical Limited's (HKG:9996) 26% Share Price Surge

Sep 09

Risks Still Elevated At These Prices As Peijia Medical Limited (HKG:9996) Shares Dive 30%

Jul 17

More Unpleasant Surprises Could Be In Store For Peijia Medical Limited's (HKG:9996) Shares After Tumbling 27%

Mar 28

More Unpleasant Surprises Could Be In Store For Peijia Medical Limited's (HKG:9996) Shares After Tumbling 29%

Jan 22

Despite Lacking Profits Peijia Medical (HKG:9996) Seems To Be On Top Of Its Debt

Oct 05

A Look At The Fair Value Of Peijia Medical Limited (HKG:9996)

Aug 29

We're Hopeful That Peijia Medical (HKG:9996) Will Use Its Cash Wisely

Mar 16

We Think Peijia Medical (HKG:9996) Can Easily Afford To Drive Business Growth

Nov 26

We're Hopeful That Peijia Medical (HKG:9996) Will Use Its Cash Wisely

Jul 30

Is Peijia Medical Limited (HKG:9996) Worth HK$28.3 Based On Its Intrinsic Value?

May 05

Could The Peijia Medical Limited (HKG:9996) Ownership Structure Tell Us Something Useful?

Mar 03

Peijia Medical Limited's (HKG:9996) Intrinsic Value Is Potentially 43% Above Its Share Price

Jan 27

We Think Peijia Medical (HKG:9996) Can Afford To Drive Business Growth

Dec 23

Opbrengsten en kosten

Hoe Peijia Medical geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.

Inkomsten en omzetgeschiedenis

SEHK:9996 Opbrengsten, kosten en inkomsten (CNY Millions )
Datum	Inkomsten	Inkomsten	G+A Uitgaven	R&D-uitgaven
30 Jun 24	517	-252	446	223
31 Mar 24	479	-322	456	214
31 Dec 23	441	-393	467	205
30 Sep 23	399	-460	457	182
30 Jun 23	357	-528	447	159
31 Mar 23	304	-468	406	153
31 Dec 22	251	-408	365	147
30 Sep 22	227	-449	325	149
30 Jun 22	204	-491	285	151
31 Mar 22	170	-533	246	141
31 Dec 21	137	-574	208	131
30 Sep 21	106	-515	176	123
30 Jun 21	76	-455	143	114
31 Mar 21	57	-1,262	141	109
31 Dec 20	39	-2,069	139	103
30 Sep 20	33	-2,128	180	92
30 Jun 20	28	-2,187	221	80
31 Mar 20	23	-1,360	201	68
31 Dec 19	19	-532	181	55

Kwaliteitswinsten: 9996 is momenteel verliesgevend.

Groeiende winstmarge: 9996 is momenteel verliesgevend.

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Winsttrend: 9996 is verlieslatend, maar heeft de verliezen de afgelopen 5 jaar met een snelheid van 38.7% per jaar verminderd.

Versnelling van de groei: Het is niet mogelijk om de winstgroei van 9996 over het afgelopen jaar te vergelijken met het gemiddelde over de afgelopen vijf jaar, omdat het bedrijf momenteel verliesgevend is.

Winst versus industrie: 9996 is verlieslatend, waardoor het lastig is om de winstgroei van het afgelopen jaar te vergelijken met die van de Medical Equipment industrie ( -4.3% ).

Rendement op eigen vermogen

Hoge ROE: 9996 heeft een negatief Return on Equity ( -11.54% ), omdat het momenteel verliesgevend is.

Peijia Medical Inkomsten in het verleden

Verleden criteriumcontroles 0/6

Belangrijke informatie

Recente prestatie-updates uit het verleden

First half 2024 earnings released: CN¥0.10 loss per share (vs CN¥0.31 loss in 1H 2023)

First half 2024 earnings released: CN¥0.10 loss per share (vs CN¥0.31 loss in 1H 2023)

Peijia Medical Limited to Report First Half, 2024 Results on Aug 23, 2024

Full year 2023 earnings: EPS and revenues miss analyst expectations

Peijia Medical Limited to Report Fiscal Year 2023 Results on Jun 15, 2024

Full year 2023 earnings: EPS and revenues miss analyst expectations

Recent updates

Peijia Medical Limited Announces Resignation of Yu Zhiyun as Non-Executive Director and A Member of the Board's Remuneration Committee

First half 2024 earnings released: CN¥0.10 loss per share (vs CN¥0.31 loss in 1H 2023)

Why Investors Shouldn't Be Surprised By Peijia Medical Limited's (HKG:9996) 26% Share Price Surge

Peijia Medical Limited, Annual General Meeting, Sep 30, 2024

Consensus EPS estimates upgraded to CN¥0.29 loss

First half 2024 earnings released: CN¥0.10 loss per share (vs CN¥0.31 loss in 1H 2023)

Peijia Medical Limited to Report First Half, 2024 Results on Aug 23, 2024

Risks Still Elevated At These Prices As Peijia Medical Limited (HKG:9996) Shares Dive 30%

Full year 2023 earnings: EPS and revenues miss analyst expectations

Less than half of directors are independent

Peijia Medical Limited to Report Fiscal Year 2023 Results on Jun 15, 2024

Full year 2023 earnings: EPS and revenues miss analyst expectations

More Unpleasant Surprises Could Be In Store For Peijia Medical Limited's (HKG:9996) Shares After Tumbling 27%

Peijia Medical Limited to Report Fiscal Year 2023 Results on Mar 28, 2024

Forecast to breakeven in 2025

Peijia Medical Announces Successful Completion of Patient Enrollment for Pivotal TaurusTrio Transcatheter Aortic Regurgitation Clinical Trial

More Unpleasant Surprises Could Be In Store For Peijia Medical Limited's (HKG:9996) Shares After Tumbling 29%

Estimating The Intrinsic Value Of Peijia Medical Limited (HKG:9996)

Does Peijia Medical (HKG:9996) Have A Healthy Balance Sheet?

Forecast to breakeven in 2025

First half 2023 earnings released: CN¥0.31 loss per share (vs CN¥0.14 loss in 1H 2022)

Peijia Medical Limited to Report First Half, 2023 Results on Aug 31, 2023

Now 22% undervalued after recent price drop

Calculating The Fair Value Of Peijia Medical Limited (HKG:9996)

Peijia Medical Limited Announces First Patient in Multi-Center Registration Clinical Trial of Taurustrio™? Transcatheter Aortic Valve Replacement System in China

Peijia Medical Limited Provides Unaudited Revenue Guidance for the Period from January 1, 2023 to June 30, 2023

New minor risk - Profitability

Peijia Medical Limited Receives Approval from the National Medical Products Administration of the PRC for the Registration Application of DCwireTM Micro Guidewire

Is Peijia Medical (HKG:9996) A Risky Investment?

Getting In Cheap On Peijia Medical Limited (HKG:9996) Is Unlikely

Executive Director & Company Secretary recently sold HK$3.1m worth of stock

Forecast to breakeven in 2025

Consensus EPS estimates fall by 73%

Are Investors Undervaluing Peijia Medical Limited (HKG:9996) By 40%?

Peijia Medical Limited Announces First Patient Enrollment in the Multi-Center Registration Clinical Trial of Geminione Transcatheter Edge-To-Edge Repair System in China

Peijia Medical Limited Announces in Partnership with inQB8 Medical Technologies, LLC Successfully Completed the First Patient Implant in the First-In-Man Clinical Trial of the MonarQ Transcatheter Tricuspid Valve Replacement System in the World

Less than half of directors are independent

Peijia Medical Limited Announces First Patient Implant in Multi-Center Registrationclinical Trial of Peijia Highlife Transcatheter Mitralvalve Replacement System in China

Despite Lacking Profits Peijia Medical (HKG:9996) Seems To Be On Top Of Its Debt

A Look At The Fair Value Of Peijia Medical Limited (HKG:9996)

First half 2022 earnings released: CN¥0.14 loss per share (vs CN¥0.27 loss in 1H 2021)

Peijia Medical Limited to Report First Half, 2022 Results on Aug 19, 2022

Forecast to breakeven in 2024

Peijia Medical Limited Announces Executive Changes

Peijia Medical Limited Receives NMPA Approval for Registration Application of Fluxcap Balloon Guide Catheter

Peijia Medical Limited Receives the Approval from the National Medical Products Administration of the PRC for the Registration Application of Tethys AS Aspiration Catheter

Peijia Medical Limited, Annual General Meeting, Jun 10, 2022

Full year 2021 earnings: EPS misses analyst expectations

Less than half of directors are independent

Full year 2021 earnings: EPS exceeds analyst expectations

Peijia Medical Limited to Report Fiscal Year 2021 Results on Mar 31, 2022

We're Hopeful That Peijia Medical (HKG:9996) Will Use Its Cash Wisely

Peijia Medical Limited Receives the Approval from the National Medical Products Administration for Syphonet® Stent Retriever

Peijia Medical Limited Announces First Patient Implant in Research Clinical Trial of Peijia's Highlife Trans-Septal Mitral Valve Replacement System in China

We Think Peijia Medical (HKG:9996) Can Easily Afford To Drive Business Growth

Peijia Medical Announces First Patient Implant in the Clinical Trial of Its Third-Generation Transcatheter Aortic Valve System TaurusNXT

Peijia Medical Limited Announces First Patient Implant in Clinical Trial of TaurusNXT

First half 2021 earnings released: CN¥0.27 loss per share (vs CN¥8.68 loss in 1H 2020)

We're Hopeful That Peijia Medical (HKG:9996) Will Use Its Cash Wisely

Peijia Medical Limited Receives the Approval from the National Medical Products Administration of the PRC of the Registration Application for TaurusElite

Is Peijia Medical Limited (HKG:9996) Worth HK$28.3 Based On Its Intrinsic Value?

Full year 2020 earnings released: CN¥4.43 loss per share (vs CN¥2.33 loss in FY 2019)

Full year 2020 earnings released: CN¥4.43 loss per share (vs CN¥2.26 loss in FY 2019)

Peijia Medical Limited to Report Fiscal Year 2020 Results on Mar 29, 2021

Could The Peijia Medical Limited (HKG:9996) Ownership Structure Tell Us Something Useful?

Peijia Medical Limited Announces Patient Enrollment for the Clinical Trial Ofshenyi Stent Retriever

Peijia Medical Limited's (HKG:9996) Intrinsic Value Is Potentially 43% Above Its Share Price

New 90-day high: HK$31.55

We Think Peijia Medical (HKG:9996) Can Afford To Drive Business Growth